August 15, 2025

A Young Hematologist’s Take on ICML 2025

From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an inn...

The ASCO Post

August 15, 2025

Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker

New research out of Spain has shown that patients with cancer who had lower levels of the biomarker CD69 (receptor on T cells) before starting treatment with immune checkpoint inhibitors (ICIs) had a ...

The ASCO Post

August 04, 2025

New Guidelines Recommend Blood-Based Biomarkers in Alzheimer's Dx

"The panel urges clinicians to consider the pretest probability of AD pathology for each patient when deciding whether or not to use a BBM test,” and not as a standalone diagnostic tool.

Conexiant

July 29, 2025

Chemo's Impact on Brain Explored

Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.

Conexiant

July 28, 2025

Race, Sex, and Steps to Cognition

Walking significantly slows cognitive decline in APOE ε4 carriers, with benefits varying by sex and race in 10-year study.

Conexiant

July 24, 2025

Perioperative Therapy With Durvalumab Plus FLOT: A Potential New Standard of Care in Gastric or Gastroesophageal Junction Cancer

In patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, perioperative treatment with the checkpoint inhibitor durvalumab in combination with standard chemotherapy signif...

The ASCO Post

May 01, 2025

Fas Inhibition Shows Neuroprotective Benefit for GA

An investigational Fas inhibitor demonstrated encouraging results in patients with geographic atrophy (GA) in a phase 1b clinical trial. In the study, eyes treated with ONL1204 (ONL Therapeutics) showed reductions in GA lesion growth at 6 months of up to 50% compared to sham-treated eyes after 2 injections spaced 3 months apart, and a 42% reduction in lesion growth compared to fellow untreated eyes after a single injection.

Retinal Physician

July 14, 2025

Video: Can Vonaprument Slow Vision Loss in GA?

David Eichenbaum, MD, and Diana Do, MD, discuss the rationale for and progress of the fully enrolled ARCHER II trial at ASRS 2025.

Retinal Physician

July 14, 2025

Video: Dual-Action Gene Therapy for DME Shows Safety and Durability

David Almeida, MD, presented interim data from the SPECTRA trial of 4D-150 gene therapy in adults with diabetic macular edema

Retinal Physician